Drug intelligence / Profile preview

CHS-2020

Development stage: Discontinued
Lead developer: Coherus BioSciences
Modality: Recombinant Proteins and Enzymes

Overview

CHS-2020 is an ophthalmology biosimilar of aflibercept (Eylea), a recombinant fusion protein. It functions by inhibiting vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, to prevent abnormal blood vessel growth and leakage in the eye, which are common in various retinal diseases. Initially developed by Coherus BioSciences, it was later divested to Sandoz as part of a strategic portfolio realignment.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on CHS-2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHS-2020.

Explore the full profile